Emergent BioSolutions (NYSE: EBS) prepays $100M on outstanding term loan

Rhea-AI Filing Summary

Emergent BioSolutions Inc. disclosed that it voluntarily prepaid $100 million in late December 2025 on its outstanding term loan under a credit agreement dated August 30, 2024. This early repayment reduces the company’s term loan balance and interest-bearing debt under that facility. The company announced the prepayment in a press release furnished as an exhibit, indicating a proactive step in managing its capital structure and obligations to its lenders.

Insights

Capital structure and credit analyst

Emergent makes a voluntary $100M term loan prepayment, trimming leverage.

Emergent BioSolutions reports a voluntary prepayment of $100 million on its outstanding term loan tied to an August 30, 2024 credit agreement. Voluntary prepayments typically indicate active balance sheet management, as they are not required by amortization schedules or mandatory sweep provisions described elsewhere.

This action decreases the company’s term loan balance and should lower future cash interest tied to that specific facility. The move also signals that sufficient liquidity was available in late December 2025 to retire a portion of debt ahead of schedule, although the broader cash and debt profile is not detailed in this excerpt.

The company highlighted the prepayment through a January 12, 2026 press release, underscoring its relevance for stakeholders tracking leverage and financing arrangements with the lenders party to the credit agreement and the administrative agent OHA Agency LLC.

0001367644false00013676442026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33137

14-1902018

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

 300 Professional Drive,

Gaithersburg, Maryland 20879

(Address of principal executive offices, including zip code)

(240) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			EBS			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01     Regulation FD Disclosure.

On January 12, 2026, Emergent Biosolutions, Inc., a Delaware corporation (the “Company”), announced that it made a voluntary prepayment of $100 million in late December 2025 under its outstanding term loan (the “Term Loan”), under that certain Credit Agreement dated as of August 30, 2024, by and among the Company, the lenders from time to time party thereto and OHA Agency LLC, as administrative agent.

A copy of the press release on January 12, 2026, announcing the Company’s prepayment of the Term Loan is furnished as Exhibit 99.1 hereto.

The information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press release issued by Emergent BioSolutions Inc. on January 12, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			EMERGENT BIOSOLUTIONS INC.
Dated: January12, 2026			By:			/s/ RICHARD S. LINDAHL
						Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial              Officer and Treasurer

FAQ

What did Emergent BioSolutions (EBS) announce in this 8-K?

Emergent BioSolutions announced that it made a voluntary prepayment of $100 million in late December 2025 on its outstanding term loan under an August 30, 2024 credit agreement.

Which loan did Emergent BioSolutions (EBS) prepay by $100 million?

The company prepaid $100 million under its outstanding term loan governed by a Credit Agreement dated August 30, 2024 with lenders party to that agreement and OHA Agency LLC as administrative agent.

When did Emergent BioSolutions (EBS) make the $100 million prepayment?

The voluntary prepayment of $100 million on the term loan was made in late December 2025, as disclosed by the company.

How did Emergent BioSolutions (EBS) communicate the term loan prepayment to the market?

The company issued a press release on January 12, 2026 announcing the voluntary prepayment, which is furnished as Exhibit 99.1 to this report.

Does the Emergent BioSolutions (EBS) 8-K filing treat the press release as filed or furnished?

The information in Item 7.01 and Exhibit 99.1 is stated as furnished, not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, unless specifically incorporated by reference in another filing.

What exhibits are included with this Emergent BioSolutions (EBS) 8-K?

The report includes Exhibit 99.1, the press release about the term loan prepayment, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.